Navigation Links
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Date:3/25/2008

er the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

HERmark and VeraTag are trademarks of Monogram Biosciences. Herceptin is a registered trademark of Genentech, Inc.

contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624 4576 Tel: 415 677 2700

amerriweather@ jeremiah.hall@

monogrambio.com fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Boston Scientific Corporation (NYSE: BSX ) ... $2 billion aggregate principal amount of its senior notes ... offering consists of $850 million of 4.50 percent notes ... due January 2020 and $300 million of 7.375 percent ... use the net proceeds for general corporate purposes, including ...
(Date:12/14/2009)... Calif., Dec. 14 Nektar Therapeutics (Nasdaq: ... has been appointed to serve on its board ... industry leader with over 35 years of experience ... "Dennis brings to Nektar extensive industry perspective at ... Howard W. Robin, President and CEO of Nektar ...
(Date:12/14/2009)... ThermoFab, a US-based thermoforming company, has completed the delivery of ... sheet metal to a plastic enclosure with a smaller footprint ... ... Shirley, MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based ... Flow Tester – helping Brookfield move from sheet metal to ...
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2
... Inc. (OTC,Bulletin Board: SCIE) announced today that Jim Dorst ... and Chief Financial Officer., Jim Hitchin the Company,s ... of,experience in public medical device, manufacturing and software firms. ... ago. With a graduate,degree in accounting, he is well ...
... New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic ... ... Resverlogix Corp.,("Resverlogix") (TSX:RVX) announced today that it has received approval by,the ... clinical,trial of oral RVX-208 in the USA. RVX-208 is a novel ...
... Nash Corporation,(Nasdaq: KNSY ) is scheduled to participate ... & Tissue" at the 2007 RBC Capital Markets,Healthcare Conference., ... in the panel,discussion on Thursday, December 13th at 8:00 ... in New York. The conference is by invitation only,however ...
Other Biology Technology:Jim Dorst Joins SpectraScience as CFO 2FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208 2FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208 3
(Date:12/13/2009)... that may help to engineer plants that take advantage ... The finding could help to engineer crops that take ... the carbon dioxide they need for photosynthesis through microscopic ... each molecule of the gas gained, they lose hundreds ... can tighten to save water when CO 2 ...
(Date:12/13/2009)... Yale University researchers has used nanosensors to measure ... time. Their findings, which appear December 13 in ... , could dramatically simplify the way physicians test ... , The teamled by Mark Reed, Yale,s ... and Tarek Fahmy, an associate professor of biomedical ...
(Date:12/13/2009)... 2009Researchers at The Scripps Research Institute have solved ... from an ancient family of enzymes can have ... addition to providing guidance for understanding other molecules ... underpinning for the protein,s possible use for combating ... research was published in the December 13, 2009 ...
Breaking Biology News(10 mins):Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Scripps Research scientists crack mystery of protein's dual function 2Scripps Research scientists crack mystery of protein's dual function 3Senior doctors launch global movement to tackle climate change 62112 1Senior doctors launch global movement to tackle climate change 62112 2Feeding the clock 10896 1Feeding the clock 10896 2Feeding the clock 10896 3Salt Really Does Boost Health Risks 62109 1
... human knees is even more common in dogs. Each ... cruciate ligament (CCL) deficiency, which is comparable to the ... method of treatment by many veterinary surgeons involves cutting ... these dogs. Now, a new minimally invasive technique with ...
... Investigator, has been named a Pew Scholar in Biomedical ... an award of $240,000 over four years. , ... on the basis of performance during education and training ... relevant to human health. The Pew Charitable Trusts seek ...
... in German . , Because of its ... tetrachloride, CCl4) can no longer be used or produced in ... other chlorinated hydrocarbons, such as chloroform (trichloromethane, CHCl3), also produce ... get rid of this unwanted substance? A team headed by ...
Other Biology News:Technique used in human ankle injuries modified to treat dogs' knees 2Julia Zeitlinger named Pew Scholar 2Fair trade 2
AedestaTM Animal Organ/Tissue Perfusion Soln....
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
...
Biology Products: